APGEApogee Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 11782
Ticker: APGE
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2023-07-14
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: APGE

Detail

Enriched 2026-08-14 20:47

Market cap: $10,183,784,744.25
Shares outstanding (class): 61,877,575
Shares outstanding (weighted): 75,687,735
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 261
Location: SAN FRANCISCO, CA
Homepage: https://www.apogeetherapeutics.com
Description: Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Market cap and share counts drift.

Funds holding this security

162 funds · 166 positions · $1.73B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, IN…	—	$445.76M	0.67%	5,295,932 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$154.90M	0.01%	1,840,364 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$95.48M	1.28%	1,134,394 NS	FIGI
JNL/T. Rowe Price Capital Appreciation Fund JNL Series Trust	—	$94.75M	0.69%	1,125,673 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$88.80M	0.12%	1,054,983 NS	FIGI
T. Rowe Price Mid-Cap Growth Fund, Inc. T. ROWE PRICE MID-CAP GROWTH FUND, INC.	—	$67.51M	0.30%	802,067 NS	FIGI
T. Rowe Price Capital Appreciation Equity ETF T. Rowe Price Exchange-Traded Funds, Inc.	TCAF	$53.44M	0.86%	634,849 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$50.38M	0.06%	598,603 NS	FIGI
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$46.92M	2.96%	557,423 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$46.72M	0.43%	555,098 NS	FIGI
VY(R) T. ROWE PRICE CAPITAL APPRECIATION PORTFO… Voya Investors Trust	—	$44.09M	0.67%	523,799 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$31.95M	0.61%	379,608 NS	FIGI
Penn Series Flexibly Managed Fund Penn Series Funds Inc	—	$31.62M	0.68%	375,718 NS	FIGI
Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust	—	$30.49M	0.33%	362,287 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$30.22M	0.25%	359,030 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERAPGE
FIGI_COMPOSITEBBG01H51WYQ5
FIGI_SHARE_CLASSBBG01H51WZL7
CIK0001974640
ISINUS03770N1019
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Apogee Therapeutics is a biopharmaceutical company developing biologics, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.